Wednesday, April 15, 2009 2:05:56 AM
Rodman & Reenshaw is hardly Goldman Sachs, and really isn't held in high regard in the investment community. They are a kind of wannabe investment bank, that would like to be as powerful and connected as a Goldman, but falls miserably short, of that lofty goal. Rodman conducts heavy telemarketing, touting their dealflow, hyping the companies that they financed, as tremendous opportunities, and undervalued assets. Once again, this is not to say that CYRX, isn't exactly what is being touted in their claims, but Rodman does peddle a lot of questionable deals. And there are a lot of bad PIPE deals being done, so touting the fact that you are the leader in PIPE transactions, is like saying you are the leader in used car sales, or the leader in originating sub-prime loans. PIPE deals can often involve toxic financing for only the worst of companies...companies that can't raise money any other way.
My guess is Rodman is acting solely in the capacity of investment banker, and that Vision Capital is the lone institutional investor. BTW: Underwriting is a term used for the pulic issuance of stock in an IPO or a secondary issuance, where the investment banking firm doing the underwriting, takes down stock, and then issues stock to retail and institutional investors, usually retaining a large position in the stock of the issuing company for themselves. It's my guess that Vision will be acquiring a substanial percentage of the ownership in the company, with Rodman only brokering the deal, and having little to no ownership. There will obviously be some dilution, but Vision is the one PIPE investor, you want having an equity stake in your company. They differ from most PIPE investors, because they don't make their money, shorting the company's stock, causing a toxic death spiral. They act more as a venture capital firm helping the company's management, by providing market support, and helping the company find additional business and investors. They are and are extremely selective and thorough in the criteria they use in selecting a company to invest in, so it speaks volumes that they chose to invest in CYRX, and it is their association with Vision, that enhances their credibility, and should insure a successful future.
Couple observations. 1) Could BOD stand for Board Of Directors? Could explain why he knew so much. I highly doubt that kind of information is deduced rather than leaked. 2) Don't think that Kaminsky is with the same VIsion Capital that is investing in CYRX.
My guess is Rodman is acting solely in the capacity of investment banker, and that Vision Capital is the lone institutional investor. BTW: Underwriting is a term used for the pulic issuance of stock in an IPO or a secondary issuance, where the investment banking firm doing the underwriting, takes down stock, and then issues stock to retail and institutional investors, usually retaining a large position in the stock of the issuing company for themselves. It's my guess that Vision will be acquiring a substanial percentage of the ownership in the company, with Rodman only brokering the deal, and having little to no ownership. There will obviously be some dilution, but Vision is the one PIPE investor, you want having an equity stake in your company. They differ from most PIPE investors, because they don't make their money, shorting the company's stock, causing a toxic death spiral. They act more as a venture capital firm helping the company's management, by providing market support, and helping the company find additional business and investors. They are and are extremely selective and thorough in the criteria they use in selecting a company to invest in, so it speaks volumes that they chose to invest in CYRX, and it is their association with Vision, that enhances their credibility, and should insure a successful future.
Couple observations. 1) Could BOD stand for Board Of Directors? Could explain why he knew so much. I highly doubt that kind of information is deduced rather than leaked. 2) Don't think that Kaminsky is with the same VIsion Capital that is investing in CYRX.
Recent CYRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 10:32:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 12:01:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 12:00:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 12:00:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:01:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:00:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:00:11 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/12/2026 08:17:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 10:10:46 PM
- Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results • PR Newswire (US) • 03/03/2026 09:05:00 PM
- Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 • PR Newswire (US) • 02/17/2026 01:00:00 PM
- Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series • PR Newswire (US) • 02/11/2026 01:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/05/2026 09:56:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2025 10:30:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/10/2025 09:10:52 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/12/2025 07:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2025 07:33:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2025 10:18:14 PM
- Cryoport Reports Third Quarter 2025 Financial Results • PR Newswire (US) • 11/04/2025 09:05:00 PM
- Cryoport Continues to Set New Benchmarks for the Global Regenerative Medicine Supply Chain • PR Newswire (US) • 10/30/2025 12:30:00 PM
